VRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vertex Pharmaceuticals Inc (VRTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive analyst sentiment, and promising drug developments. While technical indicators are neutral, the long-term growth potential outweighs short-term fluctuations.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 41.176, and moving averages are converging. Key support is at 444.259, and resistance is at 461.624. The stock is trading near support levels, which could present a buying opportunity.
Strong financial performance with 9.55% YoY revenue growth and 30.46% YoY net income growth in Q4
Positive analyst sentiment with multiple upgrades and raised price targets, reflecting confidence in the company's pipeline.
Promising drug developments, including povetacicept and other products diversifying beyond cystic fibrosis.
Hedge funds are selling, with a 149.17% increase in selling activity last quarter.
Neutral insider trading trends, showing no significant insider confidence.
Technical indicators are neutral to bearish, suggesting short-term price weakness.
In Q4 2025, Vertex reported a 9.55% YoY increase in revenue to $3.19 billion, a 30.46% YoY increase in net income to $1.191 billion, and a 30.99% YoY increase in EPS to $4.65. Gross margin slightly declined by 0.08% YoY to 85.39%.
Analysts are highly optimistic about Vertex, with multiple upgrades and raised price targets. Recent price targets range from $525 to $641, reflecting confidence in the company's pipeline and growth potential.
